Galectin Therapeutics Inc (GALT) stock
GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.91−0.11 (-3.64%)
Close on Nov 17, 2026Market cap $293.47MP/E –Yield –
Galectin Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Galectin Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $8.91M, down 68.7% year over year. For fiscal 2025 it was $14.29M, down 60.9% from the year before. Over ten years it grew 0.9% a year on average. The highest annual figure on record is $36.57M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.29M | -60.9% |
| FY2024 | Dec 31, 2024 | $36.57M | +13.8% |
| FY2023 | Dec 31, 2023 | $32.13M | +1.2% |
| FY2022 | Dec 31, 2022 | $31.74M | +33.2% |
| FY2021 | Dec 31, 2021 | $23.82M | +32.5% |
| FY2020 | Dec 31, 2020 | $17.98M | +140.7% |
| FY2019 | Dec 31, 2019 | $7.47M | +15.4% |
| FY2018 | Dec 31, 2018 | $6.47M | -44.8% |
| FY2017 | Dec 31, 2017 | $11.72M | -23.5% |
| FY2016 | Dec 31, 2016 | $15.33M | +16.9% |
| FY2015 | Dec 31, 2015 | $13.11M | +55.7% |
| FY2014 | Dec 31, 2014 | $8.43M | +48.1% |
| FY2013 | Dec 31, 2013 | $5.69M | +25.6% |
| FY2012 | Dec 31, 2012 | $4.53M | +27.4% |
| FY2011 | Dec 31, 2011 | $3.55M | +233.2% |
| FY2010 | Dec 31, 2010 | $1.07M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.14M | -34.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.23M | -65.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.93M | -82.6% |
| Q3 FY2025 | Sep 30, 2025 | $2.61M | -65.6% |
| Q2 FY2025 | Jun 30, 2025 | $3.26M | -66.8% |
| Q1 FY2025 | Mar 31, 2025 | $6.49M | -19.5% |
| Q4 FY2024 | Dec 31, 2024 | $11.11M | +35.0% |
| Q3 FY2024 | Sep 30, 2024 | $7.60M | -1.8% |
| Q2 FY2024 | Jun 30, 2024 | $9.81M | +33.1% |
| Q1 FY2024 | Mar 31, 2024 | $8.05M | -8.5% |
| Q4 FY2023 | Dec 31, 2023 | $8.23M | -8.6% |
| Q3 FY2023 | Sep 30, 2023 | $7.73M | +17.2% |
| Q2 FY2023 | Jun 30, 2023 | $7.37M | -8.7% |
| Q1 FY2023 | Mar 31, 2023 | $8.80M | +9.2% |
| Q4 FY2022 | Dec 31, 2022 | $9.01M | +53.8% |
| Q3 FY2022 | Sep 30, 2022 | $6.60M | -0.2% |
| Q2 FY2022 | Jun 30, 2022 | $8.07M | +25.2% |
| Q1 FY2022 | Mar 31, 2022 | $8.06M | +64.5% |
| Q4 FY2021 | Dec 31, 2021 | $5.86M | -8.1% |
| Q3 FY2021 | Sep 30, 2021 | $6.61M | +38.3% |
| Q2 FY2021 | Jun 30, 2021 | $6.45M | +37.8% |
| Q1 FY2021 | Mar 31, 2021 | $4.90M | +128.5% |
| Q4 FY2020 | Dec 31, 2020 | $6.37M | +67.8% |
| Q3 FY2020 | Sep 30, 2020 | $4.78M | +218.0% |
| Q2 FY2020 | Jun 30, 2020 | $4.68M | +207.6% |
| Q1 FY2020 | Mar 31, 2020 | $2.14M | +231.9% |
| Q4 FY2019 | Dec 31, 2019 | $3.80M | +218.5% |
| Q3 FY2019 | Sep 30, 2019 | $1.50M | -0.1% |
| Q2 FY2019 | Jun 30, 2019 | $1.52M | +3.1% |
| Q1 FY2019 | Mar 31, 2019 | $646.00K | -71.9% |
| Q4 FY2018 | Dec 31, 2018 | $1.19M | +19.0% |
| Q3 FY2018 | Sep 30, 2018 | $1.51M | -57.0% |
| Q2 FY2018 | Jun 30, 2018 | $1.48M | -57.1% |
| Q1 FY2018 | Mar 31, 2018 | $2.30M | -39.1% |
| Q4 FY2017 | Dec 31, 2017 | $1.00M | -70.8% |
| Q3 FY2017 | Sep 30, 2017 | $3.50M | +6.5% |
| Q2 FY2017 | Jun 30, 2017 | $3.44M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.77M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.43M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.29M | – |
See a number that looks wrong?